ML-T7, a powerful inhibitor of Tim-3, effectively disrupts its interactions with PtdSer and CEACAM1. This compound enhances the antitumor activity of adoptive transfer therapy involving cytotoxic T lymphocytes (CTLs) and CAR T cells, while also boosting T cell effector functions. Additionally, ML-T7 augments the killing activity of NK cells against tumor cells and improves the antigen-presenting capacity of dendritic cells (DCs). Demonstrating antitumor efficacy in preclinical models, ML-T7 shows potential either as a standalone treatment or in combination with Nivolumab for tumor immunotherapy research [1].
